Request that the FDA determine, pursuant to 21 CFR 314.161, whether the Reference Listed Drug (RLD) ADLARITY (Donepezil Hydrochloride Transdermal System), 5 mg/day and 10 mg/day, NDA 212304, held by Corium, LLC, was withdrawn from sale for reasons of safety or effectiveness
🏛 Food and Drug Administration (FDA)FDA-2026-P-7916
Documents
3
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Jul 17, 2026No comment period
- Supporting & Related Material· Jul 17, 2026